Black Diamond Therapeutics, Inc. (BDTX) Stock Forecast Oct. 20, 2026
Analysis updated on Oct. 20, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Black Diamond Therapeutics, Inc. (BDTX) stock forecast summary
Our AI ranks Black Diamond Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Black Diamond Therapeutics, Inc. is a small-cap company with a market capitalization of $104M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/B Ratio of 1.08x is the lowest of the 50 peers that report one.
For BDTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 358 forecast dates between 2022-08-02 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 400 forecast dates between 2022-08-02 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.8%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-20 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BDTX included.
Follow BDTX freeBDTX price chart and AI forecast
How BDTX ranks among 4020 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Black Diamond Therapeutics, Inc. (BDTX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | BDTX | Rank |
|---|---|---|
| Market Cap | $104M | 60/60 |
| P/E Ratio | 4.41x | 15/16 |
| P/B Ratio | 1.08x | 50/50 |
| EPS | $0.41 | – |
| Book Value/Share | $1.67 | – |
| Revenue/Share | $0.00 | – |
Profitability & Margins
| Metric | BDTX | Rank |
|---|---|---|
| ROIC | -47.5% | 41/53 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | BDTX | Rank |
|---|---|---|
| Current Ratio | 7.28x | 24/59 |
| D/E Ratio | 0.30x | 32/53 |
| Financial Leverage | 1.30x | 31/52 |
| Working Capital | $100M | 54/59 |
Cash Flow
| Metric | BDTX | Rank |
|---|---|---|
| Operating Cash Flow | -$33M | 20/57 |
| OCF Growth YoY | -283.7% | 16/17 |
Operational Efficiency
| Metric | BDTX | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 34/36 |
| Fixed Assets Turnover | 0.0x | 36/37 |
Income Statement
| Metric | BDTX | Rank |
|---|---|---|
| Total Revenue | $0.00M | 36/37 |
| Operating Income | -$52M | 18/54 |
| R&D Expense | $28M | 55/56 |
Dividend & Shareholder Information
| Metric | BDTX | Rank |
|---|---|---|
| Shares Outstanding | 57M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $115M | 92.1% of assets |
| Cash & Short-term Investments | $19M | 15.3% of assets |
| Total Liabilities | $29M | 23.1% of assets |
| Short-term Debt | $14M | 11.5% of assets |
BDTX quarterly financials and insider trading
Black Diamond Therapeutics, Inc. (BDTX) industry peers
Companies classified under the same SEC industry code as Black Diamond Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BDTX Black Diamond Therapeutics, Inc. | ▲ | $104M |
| AMGN Amgen Inc | ▼ | $229.74B |
| GILD Gilead Sciences, Inc. | ▶ | $189.80B |
| MRNA Moderna, Inc. | ▲ | $90.58B |
| ARGX Argenx Se | ▼ | $51.09B |
| RVMD Revolution Medicines, Inc. | ▲ | $39.04B |
| BIIB Biogen Inc. | ▼ | $34.25B |
| BNTX Biontech Se | ▲ | $22.56B |
| EXEL Exelixis, Inc. | ▼ | $15.53B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.90B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| QGEN Qiagen N.V. | ▶ | $10.10B |
| RGEN Repligen Corp | ▲ | $9.96B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.48B |
| PCVX Vaxcyte, Inc. | ▲ | $9.48B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B |
| IBRX Immunitybio, Inc. | ▲ | $8.92B |
| TWST Twist Bioscience Corp | ▲ | $8.76B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B |
| KOD Kodiak Sciences Inc. | ▲ | $5.74B |
| IMVT Immunovant, Inc. | ▲ | $5.70B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.90B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.82B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.75B |
| TARS Tarsus Pharmaceuticals, Inc. | ▶ | $3.05B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.88B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.50B |
| ADMA Adma Biologics, Inc. | ▼ | $2.48B |
| LIFE Atyr Pharma Inc | ▲ | $2.48B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.16B |
| VCEL Vericel Corp | ▶ | $2.07B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| ALVO Alvotech | ▲ | $1.80B |
| NVAX Novavax Inc | ▲ | $1.78B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.73B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.65B |
| MESO Mesoblast Ltd | ▶ | $1.55B |
| IMCR Immunocore Holdings Plc | ▼ | $1.54B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.50B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.28B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.04B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $945M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $909M |
| MGTX Meiragtx Holdings Plc | ▶ | $908M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $900M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| ODTX Odyssey Therapeutics, Inc. | ▶ | $870M |
| PRME Prime Medicine, Inc. | ▲ | $695M |
| SANA Sana Biotechnology, Inc. | ▲ | $689M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $679M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $678M |
| AURA Aura Biosciences, Inc. | ▲ | $652M |
| SLDB Solid Biosciences Inc. | ▲ | $635M |
| CADL Candel Therapeutics, Inc. | ▲ | $628M |
| DBVT Dbv Technologies S.A. | ▼ | $531M |
Where BDTX sits on the market map
Black Diamond Therapeutics, Inc. (BDTX) stock news
Loading...
Black Diamond Therapeutics, Inc. (BDTX) stock forecast FAQ
What is the Black Diamond Therapeutics, Inc. (BDTX) stock forecast?
Our AI ranks Black Diamond Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Black Diamond Therapeutics, Inc. stock predictions?
For BDTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 358 forecast dates between 2022-08-02 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 400 forecast dates between 2022-08-02 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Black Diamond Therapeutics, Inc. forecasts updated?
Black Diamond Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 20, 2026.
Which companies are Black Diamond Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, BDTX included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.